<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-29</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-29 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">104</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-30 04:08</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-23">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/23</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-24">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/24</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-25">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/25</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-26">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/26</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-27">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/27</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-28">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/28</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-29">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/29</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºå¤šé¡¹é‡è¦ç›‘ç®¡å®¡æ‰¹ä¸å¤§å‹æˆ˜ç•¥æŠ•èµ„ã€‚FDAæ‰¹å‡†äº†å¤šæ¬¾åˆ›æ–°ç–—æ³•ï¼ŒåŒ…æ‹¬Tenpointçš„è€èŠ±çœ¼æ»´çœ¼æ¶²å’Œå¼ºç”ŸDarzalex Fasproåœ¨å¤šå‘æ€§éª¨é«“ç˜¤ä¸­çš„æ–°é€‚åº”ç—‡ï¼›åŒæ—¶ï¼Œé˜¿æ–¯åˆ©åº·å®£å¸ƒå°†åœ¨ä¸­å›½æŠ•èµ„150äº¿ç¾å…ƒä»¥å¢å¼ºç»†èƒç–—æ³•å’Œæ”¾å°„æ€§å¶è”è¯ç‰©èƒ½åŠ›ï¼Œæ˜¾ç¤ºå‡ºè·¨å›½è¯ä¼å¯¹ä¸­å›½å¸‚åœºçš„é•¿æœŸæ‰¿è¯ºã€‚æ­¤å¤–ï¼ŒåŸºå› ç–—æ³•é¢†åŸŸå‡ºç°å®‰å…¨æ‹…å¿§ï¼ŒRegenxbioçš„ä¸¤é¡¹è¯•éªŒå› æ‚£è€…å‡ºç°è„‘è‚¿ç˜¤è¢«FDAæš‚åœã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>11. AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - 150äº¿ç¾å…ƒå·¨é¢æŠ•èµ„å½°æ˜¾å¯¹ä¸­å›½å¸‚åœºçš„æˆ˜ç•¥æŠ¼æ³¨ï¼Œå°†æ˜¾è‘—å¢å¼ºå…¶åœ¨ç»†èƒç–—æ³•å’Œæ”¾å°„æ€§å¶è”è¯ç‰©ç­‰å‰æ²¿é¢†åŸŸçš„èƒ½åŠ›ã€‚</p>
<p><strong>1. Tenpoint wins FDA nod for combination presbyopia eye drop</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAæ‰¹å‡†æ–°å‹è€èŠ±çœ¼æ»´çœ¼æ¶²ï¼Œå¹¶ä¼´éš2.35äº¿ç¾å…ƒèèµ„æ”¯æŒä¸Šå¸‚ï¼Œæœ‰æœ›æŒ‘æˆ˜è‰¾ä¼¯ç»´ç­‰ç°æœ‰ç–—æ³•ã€‚</p>
<p><strong>13. J&J sharpens Darzalex's edge with quadruplet FDA nod in newly diagnosed multiple myeloma</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - Darzalex Fasproè·å¾—FDAæ–°æ‰¹å‡†ç”¨äºä¸é€‚åˆå¹²ç»†èƒç§»æ¤çš„æ–°è¯Šæ–­å¤šå‘æ€§éª¨é«“ç˜¤æ‚£è€…ï¼Œå·©å›ºå…¶å¸‚åœºé¢†å…ˆåœ°ä½ã€‚</p>
<p><strong>16. Regenxbio gene therapy trials suspended by FDA over safety worries</strong> â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - å› ä¸€åå‚ä¸è€…å‡ºç°è„‘è‚¿ç˜¤ï¼ŒFDAæš‚åœä¸¤é¡¹åŸºå› ç–—æ³•è¯•éªŒï¼Œå¼•å‘å¯¹åŸºå› ç–—æ³•å®‰å…¨æ€§çš„æ–°å…³æ³¨ã€‚</p>
<p><strong>2. FDA lifts hold on an Intellia CRISPR drug trial</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAè§£é™¤å¯¹Intellia CRISPRè¯ç‰©è¯•éªŒçš„éƒ¨åˆ†æš‚åœï¼Œä½†ä¸€é¡¹è¯•éªŒä»æš‚åœï¼Œæ˜¾ç¤ºåŸºå› ç¼–è¾‘ç–—æ³•ç›‘ç®¡çš„å®¡æ…å¹³è¡¡ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘æ´»åŠ¨æ´»è·ƒï¼Œæ¶‰åŠå¤šä¸ªå‰æ²¿é¢†åŸŸã€‚Lillyä¸Seamlessè¾¾æˆæ½œåœ¨ä»·å€¼10äº¿ç¾å…ƒçš„åŸºå› ç¼–è¾‘åˆä½œï¼Œå¼€å‘å¬åŠ›æŸå¤±ç–—æ³•ï¼›Argo Biopharmaçš„siRNAç–—æ³•BWâ€‘20829è¿›å…¥IIbæœŸè¯•éªŒï¼›Agomabè®¡åˆ’é€šè¿‡IPOèèµ„æ¨è¿›çº¤ç»´åŒ–ç®¡çº¿ï¼›èµ›è¯ºè²åˆ™å‰Šå‡äº†åŒ…æ‹¬amlitelimabåœ¨å†…çš„å¤šä¸ªç ”å‘é¡¹ç›®ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): ä¸´åºŠè¯•éªŒæ–¹é¢å‡ºç°æ˜¾è‘—çš„å®‰å…¨æ€§ä¸è¿›å±•ä¿¡å·ã€‚Regenxbioçš„ä¸¤é¡¹åŸºå› ç–—æ³•è¯•éªŒå› æ‚£è€…å‡ºç°è„‘è‚¿ç˜¤è¢«FDAæš‚åœï¼Œå¼•å‘å®‰å…¨æ‹…å¿§ã€‚Intelliaçš„CRISPRè¯•éªŒåœ¨å®æ–½æ–°ä¿éšœæªæ–½åéƒ¨åˆ†æ¢å¤ã€‚ç½—æ°å±•ç¤ºäº†å…¶GLP-1æ³¨å°„å‰‚çš„æ–°æ•°æ®ï¼Œè¯•å›¾åœ¨è‚¥èƒ–ç—‡é¢†åŸŸè¿½èµ¶ã€‚Summit Therapeuticsçš„PD-1xVEGFåŒç‰¹å¼‚æ€§æŠ—ä½“è·å¾—FDAçš„PDUFAæ—¥æœŸã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>æ˜æ—¥å€¼å¾—å…³æ³¨çš„äº‹é¡¹åŒ…æ‹¬ï¼š1) åŸºå› ç–—æ³•å®‰å…¨äº‹ä»¶ï¼ˆå¦‚Regenxbioå’ŒIntelliaæ¡ˆä¾‹ï¼‰å¯èƒ½å¼•å‘çš„æ›´å¹¿æ³›è¡Œä¸šè®¨è®ºä¸ç›‘ç®¡ååº”ï¼›2) é˜¿æ–¯åˆ©åº·å¯¹ä¸­å›½çš„å¤§è§„æ¨¡æŠ•èµ„ç»†èŠ‚åŠå…¶å¯¹å…¨çƒç»†èƒç–—æ³•ç«äº‰æ ¼å±€çš„æ½œåœ¨å½±å“ï¼›3) æ¬§ç›Ÿä¸å°åº¦è‡ªç”±è´¸æ˜“åå®šä¸­å–æ¶ˆè¯å“å‡ºå£å…³ç¨çš„è¿›å±•ï¼ŒåŠå…¶å¯¹å…¨çƒä¾›åº”é“¾å’Œå®šä»·çš„å½±å“ï¼›4) èµ›è¯ºè²ä¸ºåº”å¯¹Dupixentä¸“åˆ©æ‚¬å´–è€Œè®¡åˆ’çš„140-150äº¿æ¬§å…ƒå¹¶è´­é¢„ç®—çš„å…·ä½“åŠ¨å‘ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tenpoint wins FDA nod for combination presbyopia eye drop
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-29 12:26</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.</p>
                    
                    <a href="https://www.biopharmadive.com/news/tenpoint-yuvezzi-fda-approve-presbyopia-eye-drop/810743/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lifts hold on an Intellia CRISPR drug trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 16:59</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.</p>
                    
                    <a href="https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly bets on Seamless, delving further into genetic medicine for hearing loss
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 19:09</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.</p>
                    
                    <a href="https://www.biopharmadive.com/news/eli-lilly-seamless-deal-gene-editing-hearing-loss/810694/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Regenxbio gene therapy trials suspended by FDA over safety worries
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 16:06</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.</p>
                    
                    <a href="https://www.biopharmadive.com/news/regenxbio-fda-hold-hunter-hurler-syndrome-gene-therapy/810691/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche, trailing in obesity, showcases new data for GLP-1 shot
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 16:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.</p>
                    
                    <a href="https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pipeline cuts for Sanofi; Breakthru Medicine raises $60M
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 15:42</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">âœ‚ï¸ Sanofi culls several programs: The move comes as part of its â€œregular portfolio reviews,â€ a spokesperson said in an email. One candidate affected was amlitelimab, which is no longer in mid-stage trials for alopecia ...</p>
                    
                    <a href="https://endpoints.news/sanofis-pipeline-cuts-breakthru-medicine-raises-60m/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Summit gets November PDUFA date for its PD-1xVEGF bispecific
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 15:07</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted its submission package for the experimental drug ivonescimab, a bispecific ...</p>
                    
                    <a href="https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab anticipates $182M IPO as it builds fibrosis pipeline
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 14:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO. The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol ...</p>
                    
                    <a href="https://endpoints.news/agomab-anticipates-182m-ipo-as-it-builds-fibrosis-pipeline/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi says its â‚¬15B dealmaking budget, R&amp;D spend should help ease looming Dupixent patent cliff
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 11:46</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofi says it will be able to spend between â‚¬14 billion and â‚¬15 billion on M&amp;amp;A deals this year while still being able to meet its financial commitments. â€œIt doesnâ€™t mean that we will make ...</p>
                    
                    <a href="https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tenpoint gets FDA nod for presbyopia eye drop and $235M
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 06:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Tenpoint Therapeutics landed an FDA approval for its presbyopia eye drop on Wednesday, entering a tricky commercial landscape for therapeutic alternatives to reading glasses and contacts. In conjunction with the approval ...</p>
                    
                    <a href="https://endpoints.news/tenpoint-gets-fda-nod-for-presbyopia-eye-drop-and-235m/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oral Rogaine maker Veradermics looks to raise $181M from IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 19:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO. The Connecticut biotech will garner that amount if it sells ...</p>
                    
                    <a href="https://endpoints.news/oral-rogaine-maker-veradermics-looks-to-raise-181m-from-ipo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA asks court to pause Louisiana&#39;s abortion pill fight
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 19:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration is asking a federal court to halt a case over the abortion pill mifepristone while the FDA undertakes a review of the drugâ€™s safety protocols. An ongoing mifepristone review could result in ...</p>
                    
                    <a href="https://endpoints.news/fda-asks-court-to-pause-louisianas-abortion-pill-fight/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA suspends two Regenxbio gene therapy trials after patient developed brain tumor
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has placed studies of two gene therapies from Regenxbio on hold after a five-year-old patient in one of the trials was found to have a brain tumor. The drug regulator&#39;s decision is a ...</p>
                    
                    <a href="https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: Roche predicts its breast cancer pill could become its biggest-selling drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 12:11</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Rocheâ€™s breast cancer drug giredestrant is sitting pretty. Management is hugely confident ...</p>
                    
                    <a href="https://endpoints.news/roche-predicts-its-breast-cancer-pill-could-become-its-biggest-selling-drug/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The biopharma industry outlook on 2026: Optimism and tension
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-29 19:31</span>
                        
                    </div>
                    
                    <p class="news-summary">A spike in M&amp;amp;A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector&#39;s resurgence.</p>
                    
                    <a href="https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi expects vaccine sales growth to dip amid â€˜challenging environmentâ€™
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-29 16:56</span>
                        
                    </div>
                    
                    <p class="news-summary">On a conference call, executives cited &amp;ldquo;confusion&amp;rdquo; and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026. &amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/sanofi-vaccine-sales-fourth-quarter-2025-earnings/810829/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca strengthens China ties with planned $15B investment
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-29 15:46</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca&amp;rsquo;s&amp;nbsp;investment will &amp;ldquo;span the value chain&amp;rdquo; of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.</p>
                    
                    <a href="https://www.biopharmadive.com/news/astrazeneca-china-biotech-invest-drug-manufacturing/810847/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs for cancer, arthritis and HIV on Medicareâ€™s list for 2028 price cuts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 16:51</span>
                        
                    </div>
                    
                    <p class="news-summary">Still, the medications in the latest round of negotiations &amp;mdash; which now includes &amp;ldquo;Part B&amp;rdquo; drugs given in doctors offices &amp;mdash; draw very limited revenue from Medicare, an analyst pointed out.</p>
                    
                    <a href="https://www.biopharmadive.com/news/medicare-drug-price-2028-trulicity-biktarvy-verzenio-kisqali/810688/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Halozyme buys a biotech startup; Cytokinetics launches heart drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 16:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.</p>
                    
                    <a href="https://www.biopharmadive.com/news/halozyme-surf-myqorzo-boehringer-china-gsk-rsv-epidarex/810539/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Takeda &#39;anticipated&#39; Medicare negotiations for top seller Entyvio
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 19:06</span>
                        
                    </div>
                    
                    <p class="news-summary">Incoming Takeda CEO Julie Kim says the drugmaker &#34;anticipated&#34; this week&#39;s selection of Entyvio for Medicare negotiations. But for now, the company isn&#39;t ready to comment on how the process could affect peak revenue forecasts ...</p>
                    
                    <a href="https://endpoints.news/takeda-anticipated-medicare-negotiations-for-top-seller-entyvio/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Takeda is â€˜not in favorâ€™ of Trumpâ€™s MFN deals, CEO-designate says
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 18:01</span>
                        
                    </div>
                    
                    <p class="news-summary">Takedaâ€™s incoming CEO took a firm stance against President Donald Trumpâ€™s â€œmost favored nationâ€ deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House. â€œIn general ...</p>
                    
                    <a href="https://endpoints.news/takeda-is-not-in-favor-of-trumps-mfn-deals-ceo-designate-says/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        White House postpones planned TrumpRx launch event
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 17:57</span>
                        
                    </div>
                    
                    <p class="news-summary">The White House is punting the launch of TrumpRx, the administrationâ€™s hub for direct-to-consumer websites run by large drugmakers. The event was expected to take place Friday, but itâ€™s been postponed, two sources familiar with ...</p>
                    
                    <a href="https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi vows to stay committed to vaccines as portfolio takes a hit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 16:18</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofi CEO Paul Hudson emphasized the companyâ€™s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon an mRNA-based flu vaccine program. â€œWe have to continue to ...</p>
                    
                    <a href="https://endpoints.news/sanofi-vows-to-stay-committed-to-vaccines-as-portfolio-takes-a-hit/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The disrupted fate of pharmacy startups
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 16:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Last week, the House Judiciary Committee came out with a report about CVS Healthâ€™s alleged antitrust behavior toward disruptive pharmacy models that provide digital services to other pharmacies. It details ...</p>
                    
                    <a href="https://endpoints.news/the-disrupted-fate-of-pharmacy-startups/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump looks to raise South Korea levies; Siegfried expands
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 14:42</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/trump-looks-to-raise-south-korea-levies-siegfried-expands/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca makes $15B bet on China to expand manufacturing and R&amp;D
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 13:39</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that&#39;s become a go-to place for drug R&amp;amp;D and industry dealmaking in the past year. The UK pharma ...</p>
                    
                    <a href="https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Premise Health to merge with Crossover Health to expand employer clinics
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 13:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Two companies that run on-site health clinics for employers like Google and Amazon are merging as healthcare costs continue to climb. Advanced primary care company Premise Health is acquiring competitor Crossover Health. Both run clinics ...</p>
                    
                    <a href="https://endpoints.news/premise-health-to-merge-with-crossover-health-to-expand-employer-clinics/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Following Abivax, Formation Bio licenses miR-124 drug from China
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">The French biotech Abivax was a biotech market standout for 2025. Formation Bio now wants a piece of that success. The privately-held New York pharma startup has licensed a small molecule aimed ...</p>
                    
                    <a href="https://endpoints.news/exclusive-following-abivax-formation-bio-licenses-mir-124-drug-from-china/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Flagship&#39;s Repertoire gets another autoimmune partner in Lilly
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-29 11:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Repertoire Immune Medicines has added a fourth pharmaceutical partner by teaming up with Eli Lilly. The Indianapolis pharma joins Bristol Myers Squibb and Genentech in allying with Repertoire on so-called tolerizing vaccines for autoimmune diseases ...</p>
                    
                    <a href="https://endpoints.news/flagships-repertoire-gets-another-autoimmune-partner-in-lilly/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ChenMed CEO warns against GLP-1s for seniors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 23:12</span>
                        
                    </div>
                    
                    <p class="news-summary">ChenMed CEO Chris Chen said the primary care chain isnâ€™t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to worse health outcomes among its older patients. Speaking on a ...</p>
                    
                    <a href="https://endpoints.news/chenmed-ceo-warns-against-glp-1s-for-seniors/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Round three of IRA negotiations is expected to be â€˜manageableâ€™ for pharma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 21:19</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS</p>
                    
                    <a href="https://endpoints.news/round-three-of-ira-negotiations-is-expected-to-be-manageable-for-pharma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lonza still intends to sell its capsules and health ingredients business
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 18:51</span>
                        
                    </div>
                    
                    <p class="news-summary">More than a year after Lonza announced it will sell its capsules and health business, the Swiss CDMO said it has yet to finalize the deal with a buyer. A spokesperson said it has multiple ...</p>
                    
                    <a href="https://endpoints.news/lonza-still-intends-to-sell-its-capsules-and-health-ingredients-business/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teva CEO says it has successfully transitioned into a biopharma company
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 17:18</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/teva-ceo-says-it-has-successfully-transitioned-into-a-biopharma-company/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HHS seeks to protect drugmakers from violating anti-kickback laws ahead of TrumpRx launch
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:26</span>
                        
                    </div>
                    
                    <p class="news-summary">With launch time potentially approaching for TrumpRx, HHS unveiled part of its plan to shield drugmakers from anti-kickback laws to allow them to sell their products on the new direct-to-consumer platform. The guidance â€” released via ...</p>
                    
                    <a href="https://endpoints.news/hhs-seeks-to-protect-drugmakers-from-anti-kickback-laws-ahead-of-trumprx-launch/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:37</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oncology (Cancer)/Hematologic Malignancies Approval Notifications
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:55</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA does not&amp;nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&amp;nbsp;Drugs@FDA&amp;nbsp;for the latest approvals and prescribing information for specific products.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Clinical Decision Support Software
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 16:11</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This guidance clarifies the scope of FDAâ€™s oversight of clinical decision support software intended for health care professionals (HCPs) as devices.</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GDUFA IV: Fiscal Years 2028 â€“ 2032
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 22:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information related to FDAâ€™s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Untitled Letters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 18:35</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion&#39;s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.</p>
                    
                    <a href="http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Prescription Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 15:41</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Over-The-Counter Monograph Drug User Fee Program (OMUFA)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 15:29</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Medication Health Fraud for Specific Diseases and Conditions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 19:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA has identified condition-specific medication health fraud scams that can pose significant risks to consumers.</p>
                    
                    <a href="http://www.fda.gov/drugs/medication-health-fraud/medication-health-fraud-specific-diseases-and-conditions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 16:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A Special Year, New Seal, and Renewed Commitment to the American People
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 14:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has unveiled an official agency seal which signifies the many public health strides made over 120 years.</p>
                    
                    <a href="http://www.fda.gov/news-events/fda-voices/special-year-new-seal-and-renewed-commitment-american-people" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Project Orbis
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 20:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) that provides a framework for concurrent submission and review of oncology products among international partners.</p>
                    
                    <a href="http://www.fda.gov/about-fda/oncology-center-excellence/project-orbis" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What Does FDA Approve? Part 2
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The growing spread of rumors, misinformation and disinformation about science, medicine, and the FDA, is putting patients and consumers at risk. FDA is here to provide the facts.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/what-does-fda-approve-part-2" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 â€“ present
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 15:26</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 22:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        OMUFA Reauthorization: Fiscal Years 2026 - 2030
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 17:20</span>
                        
                    </div>
                    
                    <p class="news-summary">This page is the main website for information pertaining to OMUFA reauthorization activities, including high level meeting minutes with industry while negotiations are ongoing.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/omufa-reauthorization-fiscal-years-2026-2030" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Human Drug Compounding Outsourcing Facility Fees
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-29 15:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Human Drug Compounding Outsourcing Facility Fees</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patent Certifications and Suitability Petitions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Information on patents and suitability petitions that impact the availability of generic drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:22</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Center For Immunology Science, LLC - 719933 - 01/13/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Sponsor/Investigator</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/center-immunology-science-llc-719933-01132026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-28 14:20</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">siRNA therapeutic progresses in global study for patients with elevated Lp(a)</p>
                    
                    <a href="https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-26 12:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo</p>
                    
                    <a href="https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CERo reports encouraging early data from phase 1 trial of CERâ€‘1236
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-29 10:59</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CERâ€‘T therapy shows initial safety signals and prompts protocol expansion</p>
                    
                    <a href="https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-29 10:44</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections</p>
                    
                    <a href="https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMed X launches kidney disease project in partnership with the government of Barbados
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-27 13:54</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Initiative focuses on population-specific molecular profiling</p>
                    
                    <a href="https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Akari files new patent and advances second ADC targeting CEACAM5
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-28 14:15</span>
                        
                    </div>
                    
                    <p class="news-summary">Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate</p>
                    
                    <a href="https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Gedeon Richter UK takes over UK rights to cariprazine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-27 13:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati</p>
                    
                    <a href="https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-26 11:57</span>
                        
                    </div>
                    
                    <p class="news-summary">Ovarian cancer is the fifth leading cause of deaths from cancer in women</p>
                    
                    <a href="https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">42 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 11:46</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A few months after sending an untitled letter to ARS Pharmaceuticals, taking issue with certain aspects of a TV commercial about its epinephrine nasal spray, the FDA is reiterating its concerns about Neffyâ€™s advertising language.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/ars-pharma-tv-ad-epinephrine-nasal-spray-neffy-needled-fda-untitled-letter" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofiâ€™s vaccine ambitions unfazed by â€˜politics or sentiment in the now,â€™ CEO Hudson says
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 11:22</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid mounting concerns about the state of vaccine policy in the United States, Sanofi is keeping a cool head while acknowledging that sales of its immunizations are slated to dip slightly this year. The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the entire year, reaching 7.9 billion euros (roughly $9.5 billion) for all of 2025.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/sanofi-stands-firm-against-us-policy-tumult-it-predicts-vaccine-sales-dip-26" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &#39;Relax your tight end&#39;: Novartis Super Bowl ad drafts NFL stars for cheeky prostate cancer testing push
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 16:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A year after debuting its first Super Bowl ad, Novartis is returning to advertisingâ€™s biggest stage on another awareness-raising mission, this time focusing on boosting prostate cancer screening.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/novartis-super-bowl-ad-drafts-nfl-stars-cheeky-prostate-cancer-testing-push" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 23:53</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval for Yuvezzi, a treatment for presbyopia, a common, age-related condition that makes it difficult to focus on nearby objects. The company also said that it has raised $235 million to fund the launch of the product.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/tenpoint-scores-fda-nod-vision-correction-eye-drop-yuvezzi" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 05:51</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Antheia seals 2nd series C funding close, hitting more than $175M in a year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 08:26</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia&#39;s total funding over the past year to more than $175 million when combined with other capital and new contracts with the U.S. government, according to the company.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/antheia-seals-second-close-series-c-funding-hit-175m-year" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;amp;J sharpens Darzalex&#39;s edge with quadruplet FDA nod in newly diagnosed multiple myeloma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 18:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A new FDA nod for autologous stem cell transplant-ineligible patients fortifies Darzalex Faspro&#39;s position for patients with newly diagnosed multiple myeloma.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jjs-darzalex-faspro-expands-its-first-line-offerings-fda-nod-quadruplet-multiple-myeloma" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 11:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the EU and India to carry their deal across the finish line.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/eu-looks-knock-out-pharmaceutical-export-tariffs-sweeping-free-trade-pact-india" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 16:03</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about AstraZeneca investing in China, an abandoned overdose antidote, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 14:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/29/astrazeneca-hologen-kickbacks-overdose-lilly-china/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Medicare drug prices, the EU-India trade deal, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 14:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/28/medicare-pharma-india-europe-novo-lilly-advertising/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 14:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 14:17</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 14:36</span>
                        
                    </div>
                    
                    <p class="news-summary">On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk&#39;s challenge of drug pricing provisions in the Inflation Reduction Act. As with other challenges to the IRA, the Chamber argued that the negotiations baked into the law are â€œillusory.&#34;</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novo-gets-chamber-commerce-backing-bid-bring-ira-challenge-supreme-court" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hims &amp;amp; Hers uses another Super Bowl ad to tackle healthcare affordability
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 13:21</span>
                        
                    </div>
                    
                    <p class="news-summary">The minute-long ad, which debuted online Thursday ahead of its broadcast premiere during the Feb. 8 game, starts with a stark claim: â€œRich people live longer,â€ said by the adâ€™s narrator, the rapper and actor Common.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/hims-hers-uses-another-super-bowl-ad-tackle-healthcare-affordability" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 11:26</span>
                        
                    </div>
                    
                    <p class="news-summary">The gap between Vyvanse generic sales declines and growth from new products is narrowing, the Japanese company said on its third-quarter 2025 earnings call, which detailed financial performance from the nine months ending on Dec. 31.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/takeda-still-vyvanse-slog-lifts-guidance-it-looks-ahead-new-growth" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 10:41</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of closely watched breast cancer candidate giredestrant draws near. But behind another strong earnings report, a miss from the star eye drug Vabysmo stood out.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bayer broadcasts patient stories with Tony Romo calling plays in Nubeqa drive
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-29 10:12</span>
                        
                    </div>
                    
                    <p class="news-summary">Bayer has unveiled the next play in its Nubeqa marketing strategy, tapping NFL quarterback-turned-CBS commentator Tony Romo for a campaign in support of its fast-growing prostate cancer drug.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bayer-broadcasts-patient-stories-tony-romo-calling-plays-nubeqa-drive" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The new rules of biopharma M&amp;amp;A: 4 trends driving dealmaking this year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 13:36</span>
                        
                    </div>
                    
                    <p class="news-summary">As biopharma M&amp;amp;A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Advocacy group files FOIA lawsuit to gain further clarity on Trump administration&#39;s MFN pricing deals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 15:28</span>
                        
                    </div>
                    
                    <p class="news-summary">Consumer advocacy organization Public Citizen has filed a Freedom of Information Act lawsuit against the Department of Health and Human Services and the Department of Commerce&amp;nbsp;for failing to provide documents related to President Donald Trumpâ€™s most-favored nation drug pricing deals with Pfizer and Eli Lilly.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/public-citizen-files-foia-lawsuits-against-trump-administration-mfn-pricing-deals-pfizer" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Halozyme catches M&amp;amp;A wave to snap up Surf Bio in delivery tech deal worth up to $400M
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 12:05</span>
                        
                    </div>
                    
                    <p class="news-summary">Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        American Academy of Pediatrics&#39; updated immunization schedule rebukes CDC&#39;s drastic cutbacks
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 13:15</span>
                        
                    </div>
                    
                    <p class="news-summary">The pediatric medical group recommends children be vaccinated against 18 diseases, as opposed to the federal government&#39;s recent reduction to 11.</p>
                    
                    <a href="https://www.fiercepharma.com/providers/american-academy-pediatrics-updated-immunization-schedule-rebukes-cdcs-drastic-changes" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teva, after 3rd straight year of growth, expects downturn in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 11:01</span>
                        
                    </div>
                    
                    <p class="news-summary">With a third consecutive year of sales growth under its belt, the company is expecting flat or slightly down revenues in 2026, it said.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/teva-third-year-growth-innovative-products-expects-downturn-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ro serves up Super Bowl GLP-1 campaign starring Serena Williams
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 10:58</span>
                        
                    </div>
                    
                    <p class="news-summary">Ro is bringing Serena Williams to the Super Bowl. Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam tennis championâ€™s life changed after taking GLP-1 drugs sourced from the telehealth company.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/ro-serves-serena-williams-super-bowl-glp-1-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cellares&#39; series D round draws $257M as cell therapy contractor takes operations global
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 08:52</span>
                        
                    </div>
                    
                    <p class="news-summary">With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/cellares-series-d-round-draws-257m-it-readies-commercial-production" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Boehringer Super Bowl ad recruits Octavia Spencer, SofÃ­a Vergara for mission to boost kidney testing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 14:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Boehringer Ingelheimâ€™s mission for Super Bowl LX viewers, should they choose to accept it, is to learn more about urine albumin-to-creatinine ratio screening to monitor kidney health in people with certain risk factors.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/boehringer-super-bowl-ad-recruits-octavia-spencer-sofia-vergara-mission-boost-kidney" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump administration rolls out 15 more high-profile drugs for IRA price negotiations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 17:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Even as the Trump administration works to implement its most-favored-nation pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trump-administration-rolls-out-15-more-high-profile-drugs-ira-price-negotiations" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China regulators suspend sale of Sun Pharma&#39;s dementia med after site inspection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 11:13</span>
                        
                    </div>
                    
                    <p class="news-summary">Chinaâ€™s National Medical Products Administration suspended the import, sale and use of Sun&#39;s rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/chinese-regulators-suspend-sale-sun-pharmas-dementia-med-after-site-inspection" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Servier delivers 16% revenue jump, firming up â‚¬10B ambition by 2030
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved â€œone important step closerâ€ to achieving an ambitious goal for 2030.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/servier-delivers-16-revenue-jump-firming-eu10b-ambition-2030" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: States are the next vaccine battleground
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 17:07</span>
                        
                    </div>
                    
                    <p class="news-summary">This is the web edition of STAT&#39;s D.C. Diagnosis newsletter.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 16:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Trump wants lawmakers to force pharma companies to lower their prices, but it&#39;s not clear the GOP is on board.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: How Opvee, Indiviorâ€™s powerful overdose antidote, went bust
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Opvee reverses opioid overdose more quickly than Narcan. It also can cause withdrawal symptoms. Harm reduction advocates fought it, and won.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/why-opvee-overdose-antidote-failed-harm-reduction-community-opposition/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Eli Lilly expands work on gene therapies for hearing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 14:49</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: More high-income countries have used compulsory licenses to gain access to meds, study finds
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 13:00</span>
                        
                    </div>
                    
                    <p class="news-summary">More high-income countries have used compulsory licenses to gain access to meds, study finds.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/28/pharma-compulsory-licenses-patents-medicines-wto/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Glioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.</p>
                    
                    <a href="https://www.statnews.com/2026/01/28/gene-therapy-nick-leschly-startup-altido-therapeutics-targets-glioblastoma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: New startup to develop a GLP-1 drug for addiction
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 14:40</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Roche moves obesity drug to pivotal trials after mid-stage success
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 08:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.</p>
                    
                    <a href="https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 21:11</span>
                        
                    </div>
                    
                    <p class="news-summary">The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Launch of Wegovy pill looks to be going strong so far
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 14:30</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 17:19</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Insurers blame drugmakers, hospitals for high prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 15:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus more biotech news updates, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-30 04:08</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>